NCT03055403View on ClinicalTrials.gov

First-in-Human Dose Escalation Study of M201-A in Healthy Japanese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 17, 2017

Primary Completion Date

November 28, 2017

Study Completion Date

November 28, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

M201-A Injection

Active Substance: M201-A Route of administration: continuous intravenous injection

DRUG

Placebo

Saline Placebo for M201-A Route of administration: continuous intravenous injection

Trial Locations (1)

252-0375

Clinical Trial Center, Kitasato University Hospital, THE KITASATO INSTITUTE, Sagamihara

Sponsors

Collaborators (1)

Aetas Pharma Co. Ltd.
All Listed Sponsors
collaborator

Aetas Pharma Co. Ltd.

INDUSTRY

lead

Yuji KUMAGAI

OTHER

NCT03055403 - First-in-Human Dose Escalation Study of M201-A in Healthy Japanese Subjects | Biotech Hunter | Biotech Hunter